nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CYP2B6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0348	0.0349	CbGpPWpGaD
Brompheniramine—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.034	0.0341	CbGpPWpGaD
Brompheniramine—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0294	0.0295	CbGpPWpGaD
Brompheniramine—CYP2B6—Fatty acids—CYP2A7—nicotine dependence	0.0271	0.0272	CbGpPWpGaD
Brompheniramine—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0263	0.0263	CbGpPWpGaD
Brompheniramine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0242	0.0242	CbGpPWpGaD
Brompheniramine—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.024	0.024	CbGpPWpGaD
Brompheniramine—CYP2B6—Xenobiotics—CYP2A7—nicotine dependence	0.0215	0.0216	CbGpPWpGaD
Brompheniramine—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.0211	0.0212	CbGpPWpGaD
Brompheniramine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0189	0.0189	CbGpPWpGaD
Brompheniramine—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.0182	0.0183	CbGpPWpGaD
Brompheniramine—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.0163	0.0163	CbGpPWpGaD
Brompheniramine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.015	0.015	CbGpPWpGaD
Brompheniramine—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.0148	0.0149	CbGpPWpGaD
Brompheniramine—CHRM4—Monoamine GPCRs—DRD2—nicotine dependence	0.0118	0.0118	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—DRD2—nicotine dependence	0.0113	0.0113	CbGpPWpGaD
Brompheniramine—CHRM4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00993	0.00995	CbGpPWpGaD
Brompheniramine—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00979	0.00982	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00951	0.00953	CbGpPWpGaD
Brompheniramine—CHRM4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0091	0.00913	CbGpPWpGaD
Brompheniramine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00895	0.00897	CbGpPWpGaD
Brompheniramine—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00883	0.00886	CbGpPWpGaD
Brompheniramine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00876	0.00879	CbGpPWpGaD
Brompheniramine—CHRM5—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00872	0.00874	CbGpPWpGaD
Brompheniramine—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00865	0.00867	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00864	0.00867	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNB3—nicotine dependence	0.00826	0.00828	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00806	0.00808	CbGpPWpGaD
Brompheniramine—HRH1—Monoamine GPCRs—DRD2—nicotine dependence	0.00799	0.00801	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.00796	0.00799	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.00794	0.00796	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—DRD2—nicotine dependence	0.00786	0.00788	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNA6—nicotine dependence	0.00783	0.00785	CbGpPWpGaD
Brompheniramine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00758	0.0076	CbGpPWpGaD
Brompheniramine—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00748	0.0075	CbGpPWpGaD
Brompheniramine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00725	0.00728	CbGpPWpGaD
Brompheniramine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0071	0.00713	CbGpPWpGaD
Brompheniramine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00676	0.00678	CbGpPWpGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00671	0.00673	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00669	0.00671	CbGpPWpGaD
Brompheniramine—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00667	0.00669	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00667	0.00669	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00661	0.00663	CbGpPWpGaD
Brompheniramine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00622	0.00624	CbGpPWpGaD
Brompheniramine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00617	0.00618	CbGpPWpGaD
Brompheniramine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00614	0.00616	CbGpPWpGaD
Brompheniramine—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00614	0.00616	CbGpPWpGaD
Brompheniramine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00614	0.00616	CbGpPWpGaD
Brompheniramine—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00612	0.00614	CbGpPWpGaD
Brompheniramine—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00608	0.0061	CbGpPWpGaD
Brompheniramine—CHRM2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00606	0.00608	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00577	0.00578	CbGpPWpGaD
Brompheniramine—CHRM4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00566	0.00568	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—GABRA4—nicotine dependence	0.00566	0.00568	CbGpPWpGaD
Brompheniramine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00548	0.0055	CbGpPWpGaD
Brompheniramine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00543	0.00545	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNB4—nicotine dependence	0.00543	0.00544	CbGpPWpGaD
Brompheniramine—CHRM5—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00542	0.00544	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00536	0.00538	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00524	0.00525	CbGpPWpGaD
Brompheniramine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.0052	0.00522	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNA5—nicotine dependence	0.00505	0.00506	CbGpPWpGaD
Brompheniramine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00504	0.00506	CbGpPWpGaD
Brompheniramine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.005	0.00501	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00488	0.00489	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00467	0.00468	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0046	0.00461	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNA3—nicotine dependence	0.00411	0.00413	CbGpPWpGaD
Brompheniramine—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00409	0.0041	CbGpPWpGaD
Brompheniramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00407	0.00408	CbGpPWpGaD
Brompheniramine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00401	0.00402	CbGpPWpGaD
Brompheniramine—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.004	0.00402	CbGpPWpGaD
Brompheniramine—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.00385	0.00386	CbGpPWpGaD
Brompheniramine—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00382	0.00383	CbGpPWpGaD
Brompheniramine—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00381	0.00382	CbGpPWpGaD
Brompheniramine—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0038	0.00381	CbGpPWpGaD
Brompheniramine—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00377	0.00379	CbGpPWpGaD
Brompheniramine—CHRM2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00377	0.00378	CbGpPWpGaD
Brompheniramine—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00372	0.00373	CbGpPWpGaD
Brompheniramine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00366	0.00367	CbGpPWpGaD
Brompheniramine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00365	0.00366	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNB2—nicotine dependence	0.00362	0.00363	CbGpPWpGaD
Brompheniramine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00361	0.00363	CbGpPWpGaD
Brompheniramine—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00346	0.00347	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.0034	0.00341	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—TAS2R16—nicotine dependence	0.0033	0.00331	CbGpPWpGaD
Brompheniramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0033	0.00331	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00329	0.0033	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—CHRNA4—nicotine dependence	0.00329	0.0033	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00328	0.00329	CbGpPWpGaD
Brompheniramine—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00326	0.00327	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00325	0.00326	CbGpPWpGaD
Brompheniramine—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00322	0.00323	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00315	0.00316	CbGpPWpGaD
Brompheniramine—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00309	0.0031	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00307	0.00308	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00302	0.00303	CbGpPWpGaD
Brompheniramine—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00291	0.00292	CbGpPWpGaD
Brompheniramine—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00287	0.00288	CbGpPWpGaD
Brompheniramine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00284	0.00285	CbGpPWpGaD
Brompheniramine—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00282	0.00282	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00279	0.00279	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00276	0.00276	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0027	0.00271	CbGpPWpGaD
Brompheniramine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00268	0.00269	CbGpPWpGaD
Brompheniramine—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00265	0.00266	CbGpPWpGaD
Brompheniramine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00264	0.00265	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00264	0.00265	CbGpPWpGaD
Brompheniramine—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00262	0.00263	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00259	0.00259	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00254	0.00254	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—TAS2R16—nicotine dependence	0.0025	0.00251	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—DRD2—nicotine dependence	0.00246	0.00246	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—TAS2R16—nicotine dependence	0.0024	0.0024	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00228	0.00229	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00226	0.00227	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00218	0.00219	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—FGD1—nicotine dependence	0.00216	0.00217	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00213	0.00214	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00213	0.00213	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00212	0.00212	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.0021	0.0021	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—FGD1—nicotine dependence	0.00207	0.00208	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—OPRM1—nicotine dependence	0.00206	0.00206	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—OPRM1—nicotine dependence	0.00197	0.00197	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—FGD1—nicotine dependence	0.00196	0.00197	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00195	0.00196	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—FGD1—nicotine dependence	0.00188	0.00189	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.00188	0.00188	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00187	0.00188	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00186	0.00187	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00186	0.00186	CbGpPWpGaD
Brompheniramine—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00186	0.00186	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00185	0.00186	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00183	0.00184	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00183	0.00183	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00182	0.00183	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00181	0.00182	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0018	0.0018	CbGpPWpGaD
Brompheniramine—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00175	0.00176	CbGpPWpGaD
Brompheniramine—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00173	0.00173	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00169	0.0017	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00169	0.00169	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.00168	0.00169	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.00167	0.00167	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—DRD2—nicotine dependence	0.00163	0.00164	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00154	0.00155	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00154	0.00154	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00153	0.00154	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00152	0.00152	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—DRD2—nicotine dependence	0.00149	0.00149	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TAS2R16—nicotine dependence	0.00148	0.00148	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—FGD1—nicotine dependence	0.00146	0.00147	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.00146	0.00146	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.00145	0.00146	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—FGD1—nicotine dependence	0.00144	0.00144	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—DRD2—nicotine dependence	0.00142	0.00143	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TAS2R16—nicotine dependence	0.00142	0.00142	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—OPRM1—nicotine dependence	0.00139	0.0014	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.00139	0.00139	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.00138	0.00139	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—OPRM1—nicotine dependence	0.00137	0.00137	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—FGD1—nicotine dependence	0.00133	0.00133	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.00132	0.00133	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00132	0.00132	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.00132	0.00132	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00132	0.00132	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00131	0.00132	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—FGD1—nicotine dependence	0.00131	0.00131	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.0013	0.0013	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—OPRM1—nicotine dependence	0.00116	0.00117	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—FGD1—nicotine dependence	0.00116	0.00116	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—OPRM1—nicotine dependence	0.00111	0.00112	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—FGD1—nicotine dependence	0.00111	0.00111	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—OPRM1—nicotine dependence	0.00106	0.00106	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—AKR1B10—nicotine dependence	0.00102	0.00103	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—OPRM1—nicotine dependence	0.00101	0.00101	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—DRD2—nicotine dependence	0.00101	0.00101	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.001	0.00101	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TAS2R16—nicotine dependence	0.001	0.001	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.000999	0.001	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.000997	0.001	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.000994	0.000997	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—DRD2—nicotine dependence	0.00099	0.000992	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TAS2R16—nicotine dependence	0.000984	0.000987	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—AKR1B10—nicotine dependence	0.000982	0.000984	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—DRD2—nicotine dependence	0.00084	0.000843	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—DRD2—nicotine dependence	0.000805	0.000807	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000786	0.000788	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—FGD1—nicotine dependence	0.000785	0.000787	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000784	0.000786	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.000782	0.000785	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.000781	0.000783	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.00078	0.000782	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000773	0.000776	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—FGD1—nicotine dependence	0.000772	0.000775	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.000766	0.000768	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—DRD2—nicotine dependence	0.000763	0.000765	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—DRD2—nicotine dependence	0.000731	0.000733	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—WASF2—nicotine dependence	0.000722	0.000724	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—OPRM1—nicotine dependence	0.000714	0.000716	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.000712	0.000714	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.000709	0.000711	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—OPRM1—nicotine dependence	0.000702	0.000704	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—AKR1B10—nicotine dependence	0.000693	0.000695	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—WASF1—nicotine dependence	0.000692	0.000694	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—WASF2—nicotine dependence	0.000692	0.000694	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.000691	0.000693	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.000689	0.000691	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—AKR1B10—nicotine dependence	0.000682	0.000684	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—WASF1—nicotine dependence	0.000663	0.000665	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000659	0.000661	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000645	0.000647	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—OPRM1—nicotine dependence	0.000623	0.000625	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—OPRM1—nicotine dependence	0.000597	0.000599	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—DRD2—nicotine dependence	0.000568	0.00057	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000566	0.000568	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000565	0.000566	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—DRD2—nicotine dependence	0.000559	0.000561	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000558	0.00056	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—DRD2—nicotine dependence	0.000516	0.000518	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000514	0.000516	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.000513	0.000514	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—DRD2—nicotine dependence	0.000508	0.000509	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000498	0.000499	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—WASF2—nicotine dependence	0.000489	0.00049	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.000487	0.000488	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000485	0.000487	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—WASF2—nicotine dependence	0.000481	0.000482	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—WASF1—nicotine dependence	0.000468	0.00047	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000467	0.000468	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000465	0.000467	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—WASF1—nicotine dependence	0.000461	0.000462	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000458	0.000459	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000454	0.000455	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—DRD2—nicotine dependence	0.000451	0.000452	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—DRD2—nicotine dependence	0.000432	0.000433	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—OPRM1—nicotine dependence	0.000422	0.000423	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.00042	0.000422	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000419	0.00042	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—OPRM1—nicotine dependence	0.000415	0.000416	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD2—nicotine dependence	0.000305	0.000306	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD2—nicotine dependence	0.000304	0.000305	CbGpPWpGaD
Brompheniramine—CHRM2—cardiovascular system—nicotine dependence	0.000303	0.104	CbGeAlD
Brompheniramine—CHRM3—Signaling Pathways—DRD2—nicotine dependence	0.000303	0.000304	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD2—nicotine dependence	0.0003	0.000301	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000299	0.0003	CbGpPWpGaD
Brompheniramine—CHRM4—brain—nicotine dependence	0.000277	0.0948	CbGeAlD
Brompheniramine—CHRM1—cardiovascular system—nicotine dependence	0.000276	0.0944	CbGeAlD
Brompheniramine—KCNH2—cardiovascular system—nicotine dependence	0.000219	0.0749	CbGeAlD
Brompheniramine—CHRM5—brain—nicotine dependence	0.000217	0.0741	CbGeAlD
Brompheniramine—CYP2B6—cardiovascular system—nicotine dependence	0.00018	0.0615	CbGeAlD
Brompheniramine—CYP2C9—cardiovascular system—nicotine dependence	0.000178	0.0609	CbGeAlD
Brompheniramine—KCNH2—midbrain—nicotine dependence	0.000171	0.0585	CbGeAlD
Brompheniramine—CYP2E1—cardiovascular system—nicotine dependence	0.000169	0.0577	CbGeAlD
Brompheniramine—CHRM2—brain—nicotine dependence	0.000149	0.0509	CbGeAlD
Brompheniramine—CHRM1—brain—nicotine dependence	0.000135	0.0463	CbGeAlD
Brompheniramine—CHRM3—brain—nicotine dependence	0.000121	0.0414	CbGeAlD
Brompheniramine—KCNH2—brain—nicotine dependence	0.000107	0.0368	CbGeAlD
Brompheniramine—CYP2C8—brain—nicotine dependence	9.83e-05	0.0336	CbGeAlD
Brompheniramine—CYP2B6—brain—nicotine dependence	8.82e-05	0.0302	CbGeAlD
Brompheniramine—HRH1—brain—nicotine dependence	8.61e-05	0.0295	CbGeAlD
Brompheniramine—CYP2E1—brain—nicotine dependence	8.27e-05	0.0283	CbGeAlD
Brompheniramine—CYP2D6—brain—nicotine dependence	6.55e-05	0.0224	CbGeAlD
